Contact Us
  • Events News
1 min read

San Diego convention Center: June 22 – 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

June 22- 25 – 2026

We are preparing to raise funds, with part already secured, to complete our regulatory preclinical studies, with CTA submission targeted for late 2027.

Let’s connect! #BioInternationalConvention #SanDiego #USA #AcesoTherapeutics #CysticFibrosis

  • Article details

Category

Events News

Published

June 2, 2026

Reading time

1 min read

Topic

  • Share article
  • Explore more from ACESO

Uncategorized

Research news

Recognition

Publication

Press Release

Keep reading

Related news & insights

  • Company News

SATT AxLR enters the capital of Aceso Therapeutics and supports the development of ACT-101 for cystic fibrosis

Montpellier, March 2026 — Aceso Therapeutics announces the entry of SATT AxLR into its capital, marking a new milestone in the development of its biotech focused on innovative therapies for
Read More
  • Publication

European Young Investigators Meeting (EYIM) – March 2026

European Young Investigators Meeting (EYIM) - 2026
Read More
  • Research news

Collaboration between Aceso Therapeutics and the University of Montpellier to develop a new therapy for cystic fibrosis

Montpellier, February 2026 — Aceso Therapeutics and the Université de Montpellier, in collaboration with the PhyMedExp laboratories, announce a research collaboration dedicated to the development of new therapeutic approaches for
Read More
Back to all news

Get in touch

Partner with us to redefine cystic fibrosis care.

Whether you’re an investor, strategic partner, or member of the scientific community — we’d be glad to talk.

Request Information
Investor Relations

Email

contact@aceso-therapeutics.com

Headquarters

Montpellier, France